1. Home
  2. GCO vs CLLS Comparison

GCO vs CLLS Comparison

Compare GCO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genesco Inc.

GCO

Genesco Inc.

HOLD

Current Price

$23.89

Market Cap

321.1M

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$5.23

Market Cap

299.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCO
CLLS
Founded
1924
1999
Country
United States
France
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
321.1M
299.0M
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
GCO
CLLS
Price
$23.89
$5.23
Analyst Decision
Buy
Buy
Analyst Count
3
1
Target Price
$31.33
$8.00
AVG Volume (30 Days)
171.4K
133.5K
Earning Date
12-04-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.00
N/A
Revenue
$2,382,104,000.00
$82,551,000.00
Revenue This Year
$4.60
$32.58
Revenue Next Year
$2.14
N/A
P/E Ratio
$6,453.36
N/A
Revenue Growth
2.76
129.04
52 Week Low
$16.19
$1.10
52 Week High
$44.80
$5.48

Technical Indicators

Market Signals
Indicator
GCO
CLLS
Relative Strength Index (RSI) 31.66 66.42
Support Level $22.63 $4.47
Resistance Level $24.38 $4.90
Average True Range (ATR) 1.80 0.28
MACD -1.22 0.00
Stochastic Oscillator 13.18 81.63

Price Performance

Historical Comparison
GCO
CLLS

About GCO Genesco Inc.

Genesco Inc. sells footwear, headwear, sports apparel, and accessories through four main segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: